ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Thought-provoking discussions with leaders on Next-Gen Therapies, how to prepare to get funding and how AI is changing clinical trials.
Do you want to help us improve human health and understand life on Earth? Make your mark by shaping the future to enable or deliver life-changing science to solve some of humanity’s greatest challenges.
BIO is the world’s largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The UK Pavilion will be organised by the Office for Life Sciences (OLS). Pavilion exhibitors are granted access to the partnering system, with limited location access. It is recommended that one delegate uses the exhibitor partnering access, and a second delegate purchases a Premier pass here.
Since 2021, the Swiss Biotech Day has seen remarkable growth and has become a premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships. In 2025 it attracted more than 3,000 participants from 49 countries, including 25 international delegations.
*One Nucleus members receive a 12% discount via BioPartner, please email [email protected] for more information.
Prime.io Ltd helps antibody and drug target validation teams to generate high-quality knock-in and knock-out cell models—fast. Powered by our proprietary AI designed CRISPR platform (commercial licence available), we deliver:
• 3x higher knock-in efficiency than conventional spCas9 in pool and single cancer/iPSC cell derived clone
• Up to 97% knock-out efficiency in single cancer/iPSC cell derived clone
• Reduced off-target activity and immunogenicity
• NGS-validated single-cell clones
At Cancer Research UK, we exist to beat cancer.
We have an exciting opportunity for an experienced Scientist to join our Discovery Biology function at Cancer Research Horizons. Sitting within the Bioscience department, the Discovery Biology group focuses on defining the key biological insights needed to advance drug discovery projects. The team leads biomarker discovery, investigates disease pathways and drug mechanisms of action, and provides experimental evidence to help guide early clinical strategy.
bit.bio is an award-winning spinout from the University of Cambridge. Our breakthrough technology combines synthetic and stem cell biology for the precise, efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future. To do this we need talented and curious people who want to make an impact on the future of science and therapeutics.